BeiGene Ltd.

( )
BGNE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -1.09%345.740.0%$4309.25m
BNTXBioNTech SE -0.86%292.390.0%$812.11m
NVAXNovavax, Inc. -0.27%134.9979.4%$758.79m
AMGNAmgen, Inc. 0.51%208.681.4%$526.19m
REGNRegeneron Pharmaceuticals, Inc. 2.77%592.152.7%$478.99m
SNSSSunesis Pharmaceuticals, Inc. -0.80%6.210.7%$434.10m
GILDGilead Sciences, Inc. 0.09%67.731.0%$397.88m
CCXIChemoCentryx, Inc. -3.57%33.722.9%$386.50m
ILMNIllumina, Inc. -0.85%417.193.3%$357.19m
XLRNAcceleron Pharma, Inc. 0.00%173.785.3%$335.39m
OCGNOcugen, Inc. -2.03%9.150.0%$303.34m
VRTXVertex Pharmaceuticals, Inc. -0.50%184.071.9%$274.05m
BIIBBiogen, Inc. 0.44%271.121.8%$271.81m
XENEXenon Pharmaceuticals, Inc. -0.52%30.570.4%$164.85m
CRSPCRISPR Therapeutics AG -1.70%95.060.6%$159.07m

Company Profile

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.